default author photo

Luca Hensen

University of Melbourne - Department of Microbiology and Immunology (DMI)

SCHOLARLY PAPERS

1

DOWNLOADS

79

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Long-Term Safety and Immunogenicity of an MF59-Adjuvanted Spike Glycoprotein-Clamp Vaccine for SARS-CoV-2 in Adults Aged 18–55 Years or ≥56 Years: 12-Month Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 1 Trial

Number of pages: 51 Posted: 28 Mar 2023
University of Queensland - School of Chemistry and Molecular Biosciences, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, University of Melbourne, Australian National University (ANU) - Department of Immunology and Infectious Disease, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Chemistry and Molecular Biosciences, University of Queensland - School of Medicine, Tanawell Consulting, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), Agilex Biolabs, Agilex Biolabs, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Melbourne - Department of Microbiology and Immunology (DMI), Australian National University (ANU) - Department of Immunology and Infectious Disease, University of Melbourne - WHO Collaborating Centre for Reference and Research on Influenza, University of Queensland - Institute for Molecular Bioscience, University of Queensland - School of Chemistry and Molecular Biosciences and University of Queensland - School of Chemistry and Molecular Biosciences
Downloads 79 (816,709)

Abstract:

Loading...

Clinical trial, phase 1, COVID-19 vaccine, Severe acute respiratory syndrome coronavirus 2, Spike protein, SARS-CoV-2, Molecular clamp